CPIX Cumberland Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CPIX

Price (delayed)

$1.94

Market cap

$27.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.38

Enterprise value

$29.13M

Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at ...

Highlights
Cumberland Pharmaceuticals's gross profit has increased by 21% YoY and by 4.7% QoQ
The revenue has grown by 17% YoY
The net income has shrunk by 59% YoY but it rose by 20% QoQ
Cumberland Pharmaceuticals's EPS has plunged by 58% YoY but it has increased by 19% from the previous quarter
The quick ratio has decreased by 35% YoY and by 16% QoQ
The company's debt rose by 31% YoY and by 17% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.cumberlandpharma.com
Peers: DRRX IRWD MRK PFE

Key stats

What are the main financial stats of CPIX
Market
Shares outstanding
14.4M
Market cap
$27.93M
Enterprise value
$29.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.77
Price to sales (P/S)
0.67
EV/EBIT
N/A
EV/EBITDA
70.58
EV/Sales
0.69
Earnings
Revenue
$42.01M
EBIT
-$4.92M
EBITDA
$412,717
Free cash flow
$6.38M
Per share
EPS
-$0.38
Free cash flow per share
$0.44
Book value per share
$2.51
Revenue per share
$2.88
TBVPS
$4.22
Balance sheet
Total assets
$92.93M
Total liabilities
$56.95M
Debt
$20.96M
Equity
$36.27M
Working capital
$17.29M
Liquidity
Debt to equity
0.58
Current ratio
1.6
Quick ratio
1.15
Net debt/EBITDA
2.91
Margins
EBITDA margin
1%
Gross margin
78.3%
Net margin
-13.3%
Operating margin
-13.6%
Efficiency
Return on assets
-6%
Return on equity
-14.3%
Return on invested capital
-14%
Return on capital employed
-7.6%
Return on sales
-11.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CPIX stock price

How has the Cumberland Pharmaceuticals stock price performed over time
Intraday
-1.52%
1 week
-6.73%
1 month
-17.8%
1 year
-28.68%
YTD
-13.78%
QTD
-13.78%

Financial performance

How have Cumberland Pharmaceuticals's revenue and profit performed over time
Revenue
$42.01M
Gross profit
$32.89M
Operating income
-$5.7M
Net income
-$5.57M
Gross margin
78.3%
Net margin
-13.3%
The net income has shrunk by 59% YoY but it rose by 20% QoQ
The company's net margin fell by 37% YoY but it rose by 21% QoQ
The company's operating margin rose by 36% YoY and by 28% QoQ
CPIX's operating income is up by 27% since the previous quarter and by 26% year-on-year

Growth

What is Cumberland Pharmaceuticals's growth rate over time

Valuation

What is Cumberland Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.77
P/S
0.67
EV/EBIT
N/A
EV/EBITDA
70.58
EV/Sales
0.69
Cumberland Pharmaceuticals's EPS has plunged by 58% YoY but it has increased by 19% from the previous quarter
CPIX's P/B is 41% below its 5-year quarterly average of 1.3 and 14% below its last 4 quarters average of 0.9
CPIX's equity is down by 15% year-on-year and by 6% since the previous quarter
The stock's price to sales (P/S) is 63% less than its 5-year quarterly average of 1.8 and 26% less than its last 4 quarters average of 0.9
The revenue has grown by 17% YoY

Efficiency

How efficient is Cumberland Pharmaceuticals business performance
The company's return on equity has shrunk by 88% YoY but it rose by 17% QoQ
The ROA has plunged by 50% YoY but it has grown by 22% from the previous quarter
CPIX's return on invested capital is down by 36% year-on-year but it is up by 27% since the previous quarter
Cumberland Pharmaceuticals's ROS has increased by 26% from the previous quarter but it has decreased by 24% YoY

Dividends

What is CPIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CPIX.

Financial health

How did Cumberland Pharmaceuticals financials performed over time
The total assets is 63% greater than the total liabilities
The company's total liabilities rose by 36% YoY and by 9% QoQ
The quick ratio has decreased by 35% YoY and by 16% QoQ
The company's debt is 42% lower than its equity
The debt to equity has soared by 53% YoY and by 26% from the previous quarter
The company's debt rose by 31% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.